Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMTOL: Granisetron adjunct to improve semaglutide tolerability in overweight adults without diabetes
2025-524612-11-00Phase 4Authorised
- Sponsor
- University of Tartu
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Overweight and obesity comparing Semaglutide + granisetron with Semaglutide + placebo (2 arms). Primary endpoint: Semaglutide treatment tolerability (nausea severity in first 96 hours). Planned start May 2026; status: authorised.
02
Drugs
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on 2025-524612-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524612-11-00.